Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, Arampatzis CA, Soares PR, Ciccone M, Arquati M, Cortellaro M, Rutsch W, Legrand V.
Lemos PA, et al. Among authors: cortellaro m.
Am J Cardiol. 2005 Feb 15;95(4):445-51. doi: 10.1016/j.amjcard.2004.10.008.
Am J Cardiol. 2005.
PMID: 15695126
Free article.
Clinical Trial.